The cover shows diffuse intratumoral immune cell infiltration into a Merkel cell carcinoma metastasis after intratumoral injections of G100, a toll-like receptor 4 agonist. For details, see article by Bhatia and colleagues.

Read: Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial, Terry A. Day, et al.

Read the impactful clinical trial articles collection!